ESR1 and breast carcinoma: Genetic fine-mapping studies in breast cancer suggest that cis-regulatory risk variants may disrupt DNA binding affinities of TFs, particularly for known master regulators FOXA1 and ESR1, altering the regulation of gene expression and affecting breast cancer risk1–7.